Abstract
This chapter outlines protocols that produce homogenous preparations of oligomeric and fibrillar amyloid-β peptide (Aβ). While there are several isoforms of this peptide, the 42 amino acid form is the focus because of its genetic and pathological link to Alzheimer’s disease (AD). Past decades of AD research highlight the dependence of Aβ42 function on its structural assembly state. Biochemical, cellular and in vivo studies of Aβ42 usually begin with purified peptide obtained by chemical synthesis or recombinant expression. The initial steps to solubilize and prepare these purified dry peptide stocks are critical to controlling the structural assembly of Aβ. To develop homogenous Aβ42 assemblies, we initially monomerize the peptide, erasing any “structural history” that could seed aggregation, by using a strong solvent. It is this starting material that has allowed us to define and optimize conditions that consistently produce homogenous solutions of soluble oligomeric and fibrillar Aβ42 assemblies. These preparations have been developed and characterized by using atomic force microscopy (AFM) to identify the structurally discrete species formed by Aβ42 under specific solution conditions. These preparations have been used extensively to demonstrate a variety of functional differences between oligomeric and fibrillar Aβ42. We also present a protocol for fluorescently labeling oligomeric Aβ42 that does not affect structure, as measured by AFM, or function, as measured by a cellular uptake assay. These reagents are critical experimental tools that allow for defining specific structure/function connections.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Roychaudhuri R, Yang M, Hoshi MM, Teplow DB (2009) Amyloid beta-protein assembly and Alzheimer disease. The Journal of biological chemistry 284, 4749–53.
Rahimi, F., Shanmugam, A., and Bitan, G. (2008) Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer’s disease and related disorders. Curr Alzheimer Res 5, 319–41.
Mastrangelo, I. A., Ahmed, M., Sato, T., Liu, W., Wang, C., Hough, P., and Smith, S. O. (2006) High-resolution atomic force microscopy of soluble Abeta42 oligomers. J Mol Biol 358, 106–19.
Huang, T. H., Yang, D. S., Plaskos, N. P., Go, S., Yip, C. M., Fraser, P. E., and Chakrabartty, A. (2000) Structural studies of soluble oligomers of the Alzheimer beta-amyloid peptide. J Mol Biol 297, 73–87.
Harper, J. D., Wong, S. S., Lieber, C. M., and Lansbury, P. T. (1997) Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol 4, 119–25.
Harper, J. D., Wong, S. S., Lieber, C. M., and Lansbury, P. T., Jr. (1999) Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer’s disease. Biochem 38, 8972–80.
Roher, A. E., Chaney, M. O., Kuo, Y. M., Webster, S. D., Stine, W. B., Haverkamp, L. J., Woods, A. S., Cotter, R. J., Tuohy, J. M., Krafft, G. A., Bonnell, B. S., and Emmerling, M. R. (1996) Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer’s disease. J Biol Chem 271, 20631–35.
Legleiter, J., Czilli, D. L., Gitter, B., DeMattos, R. B., Holtzman, D. M., and Kowalewski, T. (2004) Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. J Mol Biol 335, 997–1006.
Dahlgren, K. N., Manelli, A. M., Stine, W. B., Jr., Baker, L. K., Krafft, G. A., and LaDu, M. J. (2002) Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J Biol Chem 277, 32046–53.
Stine, W. B., Jr., Dahlgren, K. N., Krafft, G. K., and LaDu, M. J. (2003) In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J Biol Chem 278, 11612–22.
Manelli, A. M., Stine, W. B., Van Eldik, L. J., and LaDu, M. J. (2004) ApoE and Abeta1-42 interactions: effects of isoform and conformation on structure and function. J Mol Neurosci 23, 235–46.
Manelli, A. M., Bulfinch, L. C., Sullivan, P. M., and LaDu, M. J. (2007) Abeta42 neurotoxicity in primary co-cultures: effect of apoE isoform and Abeta conformation. Neurobiol Aging 28, 1139–47.
White, J. A., Manelli, A. M., Holmberg, K. H., Van Eldik, L. J., and LaDu, M. J. (2005) Differential effects of oligomeric and fibrillar amyloid-beta1-42 on astrocyte-mediated inflammation. Neurobiol Dis 18, 459–65.
Trommer, B. L., Shah, C., Yun, S. H., Gamkrelidze, G., Pasternak, E. S., Stine, W. B., Manelli, A., Sullivan, P., Pasternak, J. F., and LaDu, M. J. (2005) ApoE isoform-specific effects on LTP: blockade by oligomeric amyloid-beta1-42. Neurobiol Dis 18, 75–82.
Bitan, G., Fradinger, E. A., Spring, S. M., and Teplow, D. B. (2005) Neurotoxic protein oligomers – what you see is not always what you get. Amyloid 12, 88–95.
Jiang, Q., Lee, C. Y., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., Richardson, J. C., Smith, J. D., Comery, T. A., Riddell, D., Holtzman, D. M., Tontonoz, P., and Landreth, G. E. (2008) ApoE promotes the proteolytic degradation of Abeta. Neuron 58, 681–93.
Hickman, S. E., Allison, E. K., and El Khoury, J. (2008) Microglial dysfunction and defective beta-amyloid clearance pathways in aging Alzheimer’s disease mice. J Neurosci 28, 8354–60.
El Khoury, J., Toft, M., Hickman, S. E., Means, T. K., Terada, K., Geula, C., and Luster, A. D. (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nature Med 13, 432–8.
Giunta, B., Zhou, Y., Hou, H., Rrapo, E., Fernandez, F., and Tan, J. (2008) HIV-1 TAT inhibits microglial phagocytosis of Abeta peptide. Int J Clin Exp Pathol 1, 260–75.
Majumdar A, Chung H, Dolios G, Wang R, Asamoah N, Lobel P, Maxfield FR (2008) Degradation of fibrillar forms of Alzheimer’s amyloid beta-peptide by macrophages. Neurobiology of aging 29, 707–15.
Chung, H., Brazil, M. I., Soe, T. T., and Maxfield, F. R. (1999) Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer’s amyloid beta-peptide by microglial cells. J Biol Chem 274, 32301–8.
Brazil, M. I., Chung, H., and Maxfield, F. R. (2000) Effects of incorporation of immunoglobulin G and complement component C1q on uptake and degradation of Alzheimer’s disease amyloid fibrils by microglia. J Biol Chem 275, 16941–7.
Paresce, D. M., Ghosh, R. N., and Maxfield, F. R. (1996) Microglial cells internalize aggregates of the Alzheimer’s disease amyloid beta-protein via a scavenger receptor. Neuron 17, 553–65.
Parvathy S, Rajadas J, Ryan H, Vaziri S, Anderson L, Murphy GM, Jr. (2009) Abeta peptide conformation determines uptake and interleukin-1alpha expression by primary microglial cells. Neurobiology of aging 30, 1792–1804.
Li, R., Shen, Y., Yang, L. B., Lue, L. F., Finch, C., and Rogers, J. (2000) Estrogen enhances uptake of amyloid beta-protein by microglia derived from the human cortex. J Neurochem 75, 1447–54.
Chafekar, S. M., Baas, F., and Scheper, W. (2008) Oligomer-specific Abeta toxicity in cell models is mediated by selective uptake. Biochim Biophys Acta 1782, 523–31.
Simakova, O., and Arispe, N. J. (2007) The cell-selective neurotoxicity of the Alzheimer’s Abeta peptide is determined by surface phosphatidylserine and cytosolic ATP levels. Membrane binding is required for Abeta toxicity. J Neurosci 27, 13719–29.
Saavedra, L., Mohamed, A., Ma, V., Kar, S., and de Chaves, E. P. (2007) Internalization of beta-amyloid peptide by primary neurons in the absence of apolipoprotein E. J Biol Chem 282, 35722–32.
Clifford, P. M., Zarrabi, S., Siu, G., Kinsler, K. J., Kosciuk, M. C., Venkataraman, V., D’Andrea, M. R., Dinsmore, S., and Nagele, R. G. (2007) Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. Brain Res 1142, 223–36.
Smits, H. A., van Beelen, A. J., de Vos, N. M., Rijsmus, A., van der Bruggen, T., Verhoef, J., van Muiswinkel, F. L., and Nottet, H. S. (2001) Activation of human macrophages by amyloid-beta is attenuated by astrocytes. J Immunol 166, 6869–76.
Kuhnke, D., Jedlitschky, G., Grube, M., Krohn, M., Jucker, M., Mosyagin, I., Cascorbi, I., Walker, L. C., Kroemer, H. K., Warzok, R. W., and Vogelgesang, S. (2007) MDR1-P-Glycoprotein (ABCB1) Mediates Transport of Alzheimer’s amyloid-beta peptides – implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol 17, 347–53.
Liu, Y., and Schubert, D. (1997) Cytotoxic amyloid peptides inhibit cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction by enhancing MTT formazan exocytosis. J Neurochem 69, 2285–93.
Acknowledgments
We gratefully acknowledge financial support for these studies from NIH 1F32AG030256-01 (LMJ), Alzheimer’s Association NIRG-06-26957 (CY), NIH R01 AG19121 (MJL), NIH PO1AG030128-A2 (MJL), Alzheimer’s Association Zenith Award ZEN-08-89900 (MJL), and NIH (NIA) PO1AG021184 (MJL). We also gratefully acknowledge Kevin Laxton and Amy Pham for technical and intellectual contributions.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Humana Press
About this protocol
Cite this protocol
Stine, W.B., Jungbauer, L., Yu, C., LaDu, M.J. (2010). Preparing Synthetic Aβ in Different Aggregation States. In: Roberson, E. (eds) Alzheimer's Disease and Frontotemporal Dementia. Methods in Molecular Biology, vol 670. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-744-0_2
Download citation
DOI: https://doi.org/10.1007/978-1-60761-744-0_2
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-60761-743-3
Online ISBN: 978-1-60761-744-0
eBook Packages: Springer Protocols